Linked Life Data

21071691

Source:http://linkedlifedata.com/resource/pubmed/id/21071691

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2010-11-18
pubmed:abstractText
Low concentrations of prostaglandin (PG) E(2) enhance platelet aggregation, whereas high concentrations inhibit it. The effects of PGE(2) are mediated through 4 G protein-coupled receptors, termed E-type prostaglindin (EP) receptor EP1, EP2, EP3, and EP4. The platelet-stimulating effect of PGE(2) has been suggested to involve EP3 receptors. Here we analyzed the receptor usage relating to the inhibitory effect of PGE(2).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/4-(4-cyano-2-(2-(4-fluoronaphthalen-..., http://linkedlifedata.com/resource/pubmed/chemical/Aspirin, http://linkedlifedata.com/resource/pubmed/chemical/Calcium, http://linkedlifedata.com/resource/pubmed/chemical/Dinoprostone, http://linkedlifedata.com/resource/pubmed/chemical/Fibrinogen, http://linkedlifedata.com/resource/pubmed/chemical/Fibrinolytic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Methyl Ethers, http://linkedlifedata.com/resource/pubmed/chemical/Naphthalenes, http://linkedlifedata.com/resource/pubmed/chemical/ONO-AE1-329, http://linkedlifedata.com/resource/pubmed/chemical/P-Selectin, http://linkedlifedata.com/resource/pubmed/chemical/PTGER4 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Phenylbutyrates, http://linkedlifedata.com/resource/pubmed/chemical/Platelet Aggregation Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Platelet Glycoprotein GPIIb-IIIa..., http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Prostaglandin E, EP4...
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1524-4636
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
30
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2416-23
pubmed:meshHeading
pubmed-meshheading:21071691-Aspirin, pubmed-meshheading:21071691-Blood Coagulation, pubmed-meshheading:21071691-Blood Platelets, pubmed-meshheading:21071691-Calcium, pubmed-meshheading:21071691-Dinoprostone, pubmed-meshheading:21071691-Dose-Response Relationship, Drug, pubmed-meshheading:21071691-Fibrinogen, pubmed-meshheading:21071691-Fibrinolytic Agents, pubmed-meshheading:21071691-Flow Cytometry, pubmed-meshheading:21071691-Humans, pubmed-meshheading:21071691-Methyl Ethers, pubmed-meshheading:21071691-Naphthalenes, pubmed-meshheading:21071691-P-Selectin, pubmed-meshheading:21071691-Phenylbutyrates, pubmed-meshheading:21071691-Platelet Adhesiveness, pubmed-meshheading:21071691-Platelet Aggregation, pubmed-meshheading:21071691-Platelet Aggregation Inhibitors, pubmed-meshheading:21071691-Platelet Glycoprotein GPIIb-IIIa Complex, pubmed-meshheading:21071691-Receptors, Prostaglandin E, EP4 Subtype, pubmed-meshheading:21071691-Thrombosis
pubmed:year
2010
pubmed:articleTitle
The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation.
pubmed:affiliation
Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Universitaetsplatz 4, A-8010 Graz, Austria.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't